Literature DB >> 29358221

Sustained Formation of Nitroglycerin-Derived Nitric Oxide by Aldehyde Dehydrogenase-2 in Vascular Smooth Muscle without Added Reductants: Implications for the Development of Nitrate Tolerance.

Marissa Opelt1, Gerald Wölkart1, Emrah Eroglu1, Markus Waldeck-Weiermair1, Roland Malli1, Wolfgang F Graier1, Alexander Kollau1, John T Fassett1, Astrid Schrammel1, Bernd Mayer1, Antonius C F Gorren2.   

Abstract

According to current views, oxidation of aldehyde dehydrogenase-2 (ALDH2) during glyceryltrinitrate (GTN) biotransformation is essentially involved in vascular nitrate tolerance and explains the dependence of this reaction on added thiols. Using a novel fluorescent intracellular nitric oxide (NO) probe expressed in vascular smooth muscle cells (VSMCs), we observed ALDH2-catalyzed formation of NO from GTN in the presence of exogenously added dithiothreitol (DTT), whereas only a short burst of NO, corresponding to a single turnover of ALDH2, occurred in the absence of DTT. This short burst of NO associated with oxidation of the reactive C302 residue in the active site was followed by formation of low-nanomolar NO, even without added DTT, indicating slow recovery of ALDH2 activity by an endogenous reductant. In addition to the thiol-reversible oxidation of ALDH2, thiol-refractive inactivation was observed, particularly under high-turnover conditions. Organ bath experiments with rat aortas showed that relaxation by GTN lasted longer than that caused by the NO donor diethylamine/NONOate, in line with the long-lasting nanomolar NO generation from GTN observed in VSMCs. Our results suggest that an endogenous reductant with low efficiency allows sustained generation of GTN-derived NO in the low-nanomolar range that is sufficient for vascular relaxation. On a longer time scale, mechanism-based, thiol-refractive irreversible inactivation of ALDH2, and possibly depletion of the endogenous reductant, will render blood vessels tolerant to GTN. Accordingly, full reactivation of oxidized ALDH2 may not occur in vivo and may not be necessary to explain GTN-induced vasodilation.
Copyright © 2018 The Author(s).

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29358221      PMCID: PMC5933520          DOI: 10.1124/mol.117.110783

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  28 in total

Review 1.  Nitrate therapy: new aspects concerning molecular action and tolerance.

Authors:  Thomas Münzel; Andreas Daiber; Tommaso Gori
Journal:  Circulation       Date:  2011-05-17       Impact factor: 29.690

2.  Mechanism of tolerance development to organic nitrates.

Authors:  P Needleman; E M Johnson
Journal:  J Pharmacol Exp Ther       Date:  1973-03       Impact factor: 4.030

3.  Vascular bioactivation of nitroglycerin is catalyzed by cytosolic aldehyde dehydrogenase-2.

Authors:  Matteo Beretta; Gerald Wölkart; Michaela Schernthaner; Martina Griesberger; Regina Neubauer; Kurt Schmidt; Michael Sacherer; Frank R Heinzel; Sepp D Kohlwein; Bernd Mayer
Journal:  Circ Res       Date:  2011-12-29       Impact factor: 17.367

4.  Site-directed mutagenesis of aldehyde dehydrogenase-2 suggests three distinct pathways of nitroglycerin biotransformation.

Authors:  M Verena Wenzl; Matteo Beretta; Martina Griesberger; Michael Russwurm; Doris Koesling; Kurt Schmidt; Bernd Mayer; Antonius C F Gorren
Journal:  Mol Pharmacol       Date:  2011-05-02       Impact factor: 4.436

5.  Unexpected, tolerance-devoid vasomotor and platelet actions of pentaerythrityl tetranitrate.

Authors:  B Fink; E Bassenge
Journal:  J Cardiovasc Pharmacol       Date:  1997-12       Impact factor: 3.105

6.  Role of reduced lipoic acid in the redox regulation of mitochondrial aldehyde dehydrogenase (ALDH-2) activity. Implications for mitochondrial oxidative stress and nitrate tolerance.

Authors:  Philip Wenzel; Ulrich Hink; Matthias Oelze; Swaantje Schuppan; Karin Schaeuble; Stefan Schildknecht; Kwok K Ho; Henry Weiner; Markus Bachschmid; Thomas Münzel; Andreas Daiber
Journal:  J Biol Chem       Date:  2006-11-13       Impact factor: 5.157

7.  Discrepancies between nitroglycerin and NO-releasing drugs on mitochondrial oxygen consumption, vasoactivity, and the release of NO.

Authors:  Cristina Núñez; Víctor M Víctor; Remedios Tur; Alberto Alvarez-Barrientos; Salvador Moncada; Juan V Esplugues; Pilar D'Ocón
Journal:  Circ Res       Date:  2005-10-13       Impact factor: 17.367

8.  Selective arterial dilatation by glyceryl trinitrate is not associated with nitric oxide formation in vitro.

Authors:  Mark R Miller; Stuart Grant; Roger M Wadsworth
Journal:  J Vasc Res       Date:  2008-03-20       Impact factor: 1.934

Review 9.  What is the real physiological NO concentration in vivo?

Authors:  Catherine N Hall; John Garthwaite
Journal:  Nitric Oxide       Date:  2009-07-12       Impact factor: 4.427

10.  Efficient nitrosation of glutathione by nitric oxide.

Authors:  Bernd Kolesnik; Knut Palten; Astrid Schrammel; Heike Stessel; Kurt Schmidt; Bernd Mayer; Antonius C F Gorren
Journal:  Free Radic Biol Med       Date:  2013-05-07       Impact factor: 7.376

View more
  3 in total

Review 1.  Glyceryl Trinitrate: History, Mystery, and Alcohol Intolerance.

Authors:  Russell Pearson; Anthony Butler
Journal:  Molecules       Date:  2021-10-30       Impact factor: 4.411

2.  Discordance between eNOS phosphorylation and activation revealed by multispectral imaging and chemogenetic methods.

Authors:  Emrah Eroglu; Seyed Soheil Saeedi Saravi; Andrea Sorrentino; Benjamin Steinhorn; Thomas Michel
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-16       Impact factor: 12.779

3.  Multitarget Antioxidant NO-Donor Organic Nitrates: A Novel Approach to Overcome Nitrates Tolerance, an Ex Vivo Study.

Authors:  Elisabetta Marini; Marta Giorgis; Marta Leporati; Barbara Rolando; Konstantin Chegaev; Loretta Lazzarato; Massimo Bertinaria; Marco Vincenti; Antonella Di Stilo
Journal:  Antioxidants (Basel)       Date:  2022-01-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.